BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hurt AC, Hui DS, Hay A, Hayden FG. Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. Influenza Other Respir Viruses 2015;9:20-31. [PMID: 25399715 DOI: 10.1111/irv.12293] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL, Sanchez JL, Hiser MJ, Gaydos CA. Respiratory Infections in the U.S. Military: Recent Experience and Control. Clin Microbiol Rev 2015;28:743-800. [PMID: 26085551 DOI: 10.1128/CMR.00039-14] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
2 Wei F, Gao C, Wang Y. The role of influenza A virus-induced hypercytokinemia. Crit Rev Microbiol 2021;:1-17. [PMID: 34353210 DOI: 10.1080/1040841X.2021.1960482] [Reference Citation Analysis]
3 Rodriguez P, Pérez-Morgado MI, Gonzalez VM, Martín ME, Nieto A. Inhibition of Influenza Virus Replication by DNA Aptamers Targeting a Cellular Component of Translation Initiation. Mol Ther Nucleic Acids 2016;5:e308. [PMID: 27070300 DOI: 10.1038/mtna.2016.20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ison MG. Antiviral Treatments. Clin Chest Med 2017;38:139-53. [PMID: 28159156 DOI: 10.1016/j.ccm.2016.11.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
5 Sparrow E, Friede M, Sheikh M, Torvaldsen S, Newall AT. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine 2016;34:5442-8. [PMID: 27622299 DOI: 10.1016/j.vaccine.2016.08.057] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
6 Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers 2015;104:291-309. [PMID: 25663018 DOI: 10.1002/bip.22623] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
7 Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis 2015;28:221-4. [PMID: 25918956 DOI: 10.1097/QCO.0000000000000161] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
8 Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018;8:9633. [PMID: 29941893 DOI: 10.1038/s41598-018-27890-4] [Cited by in Crossref: 169] [Cited by in F6Publishing: 159] [Article Influence: 42.3] [Reference Citation Analysis]
9 Schmidt H, Das A, Nam H, Yang A, Ison MG. Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: A 6-year retrospective study. Influenza Other Respir Viruses 2019;13:331-8. [PMID: 30977284 DOI: 10.1111/irv.12643] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Hui DSC, Lee N, Chan PKS. A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region. Respirology 2017;22:1300-12. [PMID: 28677861 DOI: 10.1111/resp.13114] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
11 Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 2017;11:240-6. [PMID: 28146320 DOI: 10.1111/irv.12446] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 16.2] [Reference Citation Analysis]
12 Tonelli M, Naesens L, Gazzarrini S, Santucci M, Cichero E, Tasso B, Moroni A, Costi MP, Loddo R. Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus. Eur J Med Chem 2017;135:467-78. [PMID: 28477572 DOI: 10.1016/j.ejmech.2017.04.070] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]